Prescribing Bupropion

Why Bupropion Matters

Reach for bupropion when the problem is too little energy, drive, or interest rather than too much anxiety or agitation. It is the only widely used antidepressant that causes weight loss instead of weight gain, and one of the few that reliably spares (and sometimes enhances) sexual function. On average it works about as well as an SSRI for major depression (roughly a dozen head-to-head trials show no meaningful difference in overall efficacy), but it gets there through a completely different mechanism and leaves a completely different side effect footprint.

The side effect footprint is why it earns a first-line spot. Most patients quit an SSRI not because it failed but because of what it did to their libido, their weight, or their emotional range. Bupropion avoids all three. It is activating rather than sedating, it produces almost no discontinuation syndrome, and it carries so few pharmacokinetic interactions that it slots cleanly into complicated regimens. With its FDA-approved role in smoking cessation and its usefulness for the fatigue-and-anhedonia phenotype of depression, it belongs in every prescriber's core rotation as a considered first choice, not a fallback.

Part 1: Indications

FDA-Approved Uses

• Major depressive disorder (monotherapy)
• Seasonal affective disorder (prevention of major depressive episodes with a seasonal pattern)
• Smoking cessation (marketed as Zyban for this indication)

Bupropion has never carried an FDA adjunct/augmentation indication. Today its practical, evidence-based augmentation role (adding it to a serotonergic antidepressant) is off-label but common and well supported.

The Evidence-Based Clinical Uses

The fatigue-anhedonia-low-motivation phenotype

Bupropion suits this phenotype best. When a depressed patient's dominant complaints are low energy, hypersomnia, psychomotor slowing, apathy, and "I just can't get myself going," its dopaminergic/noradrenergic activation matches the problem. Bupropion outperforms SSRIs for hypersomnia and fatigue and directly targets the "drive factor" (initiative, interest, energy) rather than the "distress factor" (anxiety, irritability).

The patient who can't afford SSRI side effects

Reach for bupropion first when the patient:

• Cannot tolerate or dreads sexual dysfunction (bupropion causes almost none and may raise libido)
• Has weight concerns or obesity (it is the only antidepressant that causes weight loss)
• Has comorbid or subclinical ADHD symptoms (the mild stimulant effect helps focus and drive)
• Wants to avoid emotional blunting/apathy (less common than with SSRIs)
• Is a smoker who wants to quit (one drug treats both)
• Had a prior positive response to amphetamines/stimulants: these patients are, in effect, preselected to respond to a dopaminergic agent, and bupropion gives them that pharmacology without addiction potential

Augmentation and treatment-resistant depression

Bupropion is one of the standard options for the SSRI partial responder. In STAR*D, adding bupropion SR to citalopram in non-remitters produced a ~30% remission rate (numerically similar to buspirone augmentation but better tolerated: 12.5% vs 20.6% discontinued for side effects). Switching to bupropion SR in Celexa failures yielded ~21% remission, statistically indistinguishable from switching to venlafaxine (~25%) or sertraline (~18%). Its distinct mechanism makes it a rational add-on to a serotonergic agent: you cover the residual anergy and sexual side effects the SSRI left behind.

Inflammatory depression

Patients with elevated CRP respond better to dopaminergic/noradrenergic agents (bupropion, nortriptyline) than to SSRIs; low CRP (<1 mg/L) favors SSRIs. You would not order a CRP solely to pick an antidepressant, but if one is already on the chart, or the patient is obese, which raises baseline CRP, it nudges toward bupropion. Bupropion does not lower the inflammatory markers; it simply works better in that phenotype.

Smoking cessation

Bupropion more than doubles one-year abstinence rates, with roughly 20% of patients still abstinent at one year. Mechanistically it blocks nicotinic receptors and blunts the dopamine reward of smoking; patients often report cigarettes become "actively disgusting." A useful counseling number: about half of patients who stay abstinent through the first three weeks make it to one year. Standard regimen (SR): begin 150 mg/day while the patient is still smoking, increase after 3 days to 150 mg twice daily at least 8 hours apart, set the target quit date within the first 2 weeks of treatment, and continue for 7 to 12 weeks (longer if relapse risk is high: tobacco is far more dangerous than bupropion).

Emerging: cognition in older adults

Low-dose bupropion is among the better-tolerated cognitive/energy enhancers in older adults with medical comorbidity, useful when late-life depression comes bundled with low energy and subjective cognitive complaints.

Who Is a Poorer Candidate?

• Anxiety-predominant depression. The stimulant effect can worsen anxiety, but the traditional teaching overstates this. In a meta-analysis of anxious depression, response was 59% on bupropion vs 65% on SSRIs, only a 6-point gap, and bupropion patients achieved anxiety reductions "almost as great" as SSRI patients. So this is a lean, not an absolute rule: a patient with mild anxious features who badly needs the sexual/weight/energy profile can still do well.
• Acute agitation or prominent restlessness: adding activation to activation is counterproductive.
• Patients with a seizure disorder or seizure-lowering conditions (see Part 6 and contraindications).

Part 2: Workup and Candidacy

The workup is easy, and that counts in the drug's favor. Bupropion requires no therapeutic drug levels, no baseline labs beyond a standard depression workup, and no routine ECG. There is no narrow window to defend and nothing to titrate to a serum number.

At baseline, what matters is a short screen for seizure risk and for the conditions that make activation dangerous.

That is the entire pre-start assessment for most patients. No blood draw is mandatory.

Part 3: How to Start and Dose

Formulations

Start with generic XL. It is cheap, once-daily, and what patients stay on. (Aplenzin, a branded hydrobromide-salt XL, offers no clinical advantage at higher cost; skip it.)

Standard XL Titration

• Start: 150 mg XL every morning × ~4 weeks. Morning dosing is deliberate: this drug is activating, and evening doses buy insomnia.
• Week ~4: increase to 300 mg XL every morning if tolerated. This is the standard target dose for most patients.
• Week ~8: if partial response, increase to 450 mg XL/day (the maximum).
• Maximum: 450 mg/day (XL); 400 mg/day (SR). Do not exceed these; the ceiling exists to keep seizure risk low.

The First Two Weeks: Set Expectations

Warn every patient that the opening stretch is a "roller coaster": unpredictable ups and downs, jitteriness, maybe some insomnia, that typically settles by weeks 2-4. Two things follow from this.

• Stimulant effects can appear within hours to days (focus, jitters, a lift in energy). This is not yet the antidepressant effect.
• The true antidepressant effect emerges over weeks 2-4, and you need 6-7 weeks at an adequate dose before calling it a failure.

The single most common reason patients quit is early jitteriness in days 1-5. Preempt it: normalize the sensation, and have a plan (below) ready.

Managing Overstimulation at Start

If a patient is too activated on 150 mg XL:

1. Slow down. Switch to IR 75 mg and increase by 75 mg roughly weekly, which is the gentlest possible ramp.
2. Switch XL → SR if the problem is specifically night-time stimulation/insomnia (see below).
3. Wait it out when mild, since tolerance to the jitteriness often develops within days.
4. A short course of a low-dose benzodiazepine can bridge a sensitive patient through the first weeks if needed.

The Insomnia Fix

If XL taken in the morning still disrupts sleep, the likely culprit is slow metabolism: the "12-hour" XL is lingering past 12 hours and never fully clearing before bed. The fix is to switch from XL to SR. The SR's ~8-hour release still gives you effective daytime coverage but washes out at night. (The other error to correct is dosing later in the day. Keep bupropion in the morning, or morning plus early afternoon for SR.)

The Booster Trick

If XL helps the morning but the patient slumps in the afternoon, you can add a single IR 75 mg dose in the early afternoon on top of the XL base, extending daytime coverage without moving to a higher once-daily dose.

A Note on "Above-Label" Dosing

Psychopharmacology practice occasionally pushes past PDR maximums in refractory cases, but the estimated seizure incidence rises almost tenfold between 450 and 600 mg/day, and no trial supports dosing above 450 mg. For the overwhelming majority of prescribers and patients, 450 mg XL is a hard ceiling.

Dose Adjustments and Special Populations

• Hepatic impairment: in moderate-to-severe impairment (Child-Pugh 7–15), cap XL at 150 mg every other day (SR at 100 mg/day or 150 mg every other day); use reduced dose and/or frequency even in mild impairment.
• Renal impairment: reduce the dose and/or frequency, because bupropion's active metabolites (hydroxybupropion and others) are renally cleared and accumulate.
• Geriatric: clearance is reduced and metabolites accumulate; start low and consider the lower end of the range.
• Pediatric: not FDA-approved.
• Seizure threshold: contraindicated in seizure disorders, in current or prior bulimia/anorexia nervosa, and with abrupt discontinuation of alcohol/benzodiazepines/barbiturates/antiepileptics. Respecting the labeled maxima and single-dose limits keeps the seizure rate near the ~0.1% the label reports for sustained-release at doses up to 300 mg/day.

Stopping and Switching

• Discontinuation: bupropion has a mild discontinuation profile; a formal taper is usually unnecessary, though gradual reduction is reasonable after prolonged high-dose use.
• MAOI washout: allow 14 days in each direction between bupropion and an MAOI.

Part 4: Monitoring

Monitoring is light. There is no level to draw, no routine ECG, and no mandated lab schedule.

What to do:

• Follow up every 2-4 weeks during titration, watching for overstimulation (jitters, insomnia, tachycardia, appetite suppression, emergent anxiety or agitation).
• Recheck blood pressure at follow-up, particularly in patients with baseline hypertension: the sympathomimetic effect is mild but real.
• Screen for emergent activation/mania, especially in anyone with a bipolar diathesis.
• Track weight (usually a welcome downward trend).
• Allow 6-7 weeks at an adequate dose before judging efficacy.

Part 5: Side Effects and How to Manage Them

Most bupropion side effects are the predictable consequence of stimulation. They are worst early, and most either resolve with time or respond to a slower titration or a formulation switch.

Overstimulation (CNS/Autonomic)

Overstimulation is the main problem: jitteriness, shakiness, tachycardia, insomnia, poor appetite, emergent anxiety or restlessness. It is usually early and often transient. Short-term discontinuation rates run higher than with SSRIs, driven almost entirely by this early jitteriness.

Management:

• Slow the titration (IR 75 mg weekly increments).
• Lower the dose or hold at a tolerated level.
• Switch XL → SR if the problem is nocturnal (insomnia).
• Reassure: tolerance frequently develops within days.
• If intolerable despite these steps, the patient may simply be an "SSRI person"; switch.

Insomnia

Management: dose in the morning (never at night); if XL still disrupts sleep, switch to SR to allow nighttime washout; a low-dose sedating agent (e.g., trazodone 50-100 mg QHS) is a reasonable add-on if the drug is otherwise working well.

Appetite Suppression / Weight Loss

Most patients welcome it, and it supports bupropion's use in obese and weight-conscious patients. Monitor it, and counsel underweight patients or those with restrictive eating (eating disorders are a contraindication because of the seizure risk).

Dry Mouth

Common and easy to overlook, but chronic dry mouth raises dental caries risk. Recommend OTC saliva substitutes, Biotene mouthwash/toothpaste, adequate hydration, and regular dental checkups.

Sexual Function

Sexual dysfunction is rare, and libido may improve; that is the drug's main advantage. When switching a patient off an SSRI for sexual side effects, bupropion monotherapy resolves the problem without stacking on an antidote drug (sildenafil, buspirone, etc.). Bupropion is also a first-choice augmenting agent to rescue SSRI-induced sexual dysfunction, though the evidence for that specific use is modest.

Cardiovascular

Mild sympathomimetic effect: modest increases in heart rate and blood pressure. Check BP at baseline and follow-up; treat uncontrolled hypertension before starting. It does not prolong the QT interval, an advantage over citalopram/escitalopram and the tricyclics.

Neuropsychiatric Cautions

• Anxiety/agitation: the activation itself; managed as overstimulation above.
• Mania/hypomania: activation can flip a bipolar patient; don't use as monotherapy in bipolar disorder.

The Comparative Profile (Why Patients Stay On It)

• No weight gain (weight loss instead): opposite of SSRIs/SNRIs and especially mirtazapine
• No sexual dysfunction
• No sedation (energizing)
• Minimal emotional blunting
• Minimal withdrawal on discontinuation
• Low bleeding risk (unlike serotonergic agents, which impair platelet aggregation)

Part 6: Seizure Risk, Overdose, and Boxed Warning

Bupropion's one distinctive safety issue is dose-dependent seizure risk, and the drug's history explains the caution.

The History and the Numbers

• 1986: immediate-release bupropion (marketed from 1985) produced an alarming seizure rate at the doses then permitted; the label still records that the estimated incidence rises almost tenfold between 450 and 600 mg/day. The drug was pulled from the market in 1986.
• 1989 reintroduction with a 450 mg/day ceiling: in a large prospective follow-up study the incidence with immediate-release at 300 to 450 mg/day was about 0.4% (13/3200).
• Sustained-release at up to 300 mg/day: the incidence was about 0.1% (1/1000).
• The extended-release formulations (SR, XL) smooth the peak plasma levels that drive seizures, so they are now standard and IR high-dose regimens are obsolete.

Contraindications Tied to Seizure Risk

• Seizure disorder or seizure predisposition (head trauma, CNS tumor, prior seizure)
• Bulimia or anorexia nervosa, current or past
• Abrupt discontinuation of alcohol or benzodiazepines (a high-risk withdrawal state)
• MAOI use within 14 days

Overdose

Bupropion is relatively safe in overdose compared with the tricyclics: no comparable cardiotoxic lethality. The dominant concern in overdose is seizures (and, at large ingestions, cardiac and CNS toxicity). There is no specific antidote; management is supportive (airway, seizure control, cardiac monitoring, and prolonged observation, since extended-release ingestions can seize late). Any significant overdose needs emergency-department evaluation.

Boxed Warning

Part 7: Drug Interactions

Bupropion is one of the cleanest antidepressants for polypharmacy: few interactions, and no serotonin-syndrome risk. But you need to know one enzyme effect well.

Bupropion Is a Strong CYP2D6 Inhibitor

Bupropion (and its metabolites) potently inhibit CYP2D6, so it raises levels of 2D6 substrates.

• Antipsychotics metabolized by 2D6 (risperidone, aripiprazole)
• Atomoxetine, many tricyclics, certain beta-blockers, tamoxifen
• Dextromethorphan (the basis of the Auvelity combination, see below)
• Prodrugs that need 2D6 to activate (codeine, tramadol) may have reduced analgesic effect, because they can't be converted to their active form

When co-prescribing a 2D6 substrate, anticipate accumulation and consider dose adjustment. (A newer example: xanomeline/trospium exposure rises with a strong 2D6 inhibitor like bupropion, and its label calls for closer monitoring for adverse reactions when the two are combined.)

Auvelity (Bupropion + Dextromethorphan)

This fixed-dose combination uses the 2D6 interaction deliberately, for therapeutic effect: bupropion blocks dextromethorphan's metabolism, extending its half-life from ~4 hours to ~22 hours and raising exposure dramatically (peak ~40-fold, AUC ~60-fold), so the dextromethorphan can act as a rapid NMDA-modulating antidepressant. Two implications for your own prescribing:

• Do not combine dextromethorphan-containing products with potent 2D6 inhibitors (fluoxetine, paroxetine, duloxetine): you compound the effect and raise serotonin-syndrome risk.
• Be aware the interaction can push dextromethorphan into a misusable range.

Things That Lower Bupropion Levels (via Enzyme Induction)

• Carbamazepine (a potent inducer)
• Cigarette smoking belongs on this list only to be ruled out: the label reports no statistically significant difference in Cmax, half-life, Tmax, AUC or clearance of bupropion or its active metabolites between smokers and nonsmokers, so quitting does not call for a dose change.
• Cannabis may induce; changes in use can shift levels.

MAOIs

This is a hard rule: do not combine bupropion with an MAOI, and observe a 14-day washout in either direction. Given bupropion's noradrenergic/dopaminergic activity, the combination risks hypertensive reactions.

Additive Effects

• Alcohol and other seizure-threshold-lowering agents compound seizure risk: counsel moderation.
• CNS depressants (benzodiazepines, opioids): additive sedation, though minor for an activating drug.

What Bupropion Does Not Do

• No serotonin syndrome risk on its own: it is not serotonergic.
• No meaningful QT effect.
• Low bleeding risk (safe alongside NSAIDs/anticoagulants from a platelet standpoint).

Part 8: Special Populations

Pregnancy

Human data are more reassuring than the drug's caution suggests. Bupropion has not been convincingly linked to a clear pattern of major malformations, and it is sometimes chosen in pregnancy specifically to avoid the sexual/weight burden of alternatives. It is also the antidepressant with the most direct value for a pregnant patient who wants to stop smoking, where the drug's benefit is substantial. The chief theoretical concern is still seizure threshold, which matters in a patient with any predisposing factor. As always, the decision balances medication exposure against the well-documented harms of untreated maternal depression. Individualize, document the risk-benefit conversation, and coordinate with obstetrics.

Breastfeeding

Bupropion is excreted into breast milk, and there are scattered case reports of possible infant seizures, so many authorities are cautious. This does not make it absolutely contraindicated (relative infant dose is generally low), but in a breastfeeding patient, use the lowest effective dose, monitor the infant (feeding, sleep, any abnormal movements), and coordinate with pediatrics. For a patient already stable and doing well on bupropion, continuation is often reasonable.

Elderly (≥65)

• Start low, go slow, but still aim for a full therapeutic dose.
• The activating profile may be less well tolerated (jitteriness, insomnia, appetite loss); watch closely.
• Seizure risk persists: screen for predisposing factors and polypharmacy.
• Upsides in this group: no anticholinergic burden, no orthostatic hypotension/fall risk (unlike trazodone/mirtazapine/TCAs), and possible cognitive/energy benefit in late-life depression with fatigue.

Renal Impairment

Bupropion and its active metabolites can accumulate when clearance falls. In significant renal impairment (roughly CrCl <30 mL/min), reduce the dose and frequency: a common approach caps around 150 mg/day and avoids aggressive titration, since accumulating metabolites can raise seizure risk. Monitor clinically.

Hepatic Impairment

• Mild impairment (Child-Pugh 5 to 6): consider reducing the dose and/or frequency of dosing.
• Moderate to severe impairment (Child-Pugh 7 to 15): the maximum is 150 mg every other day (SR: 100 mg/day or 150 mg every other day).
• Severe cirrhosis: use with real caution, at reduced dose and extended intervals, and avoid the once-daily XL in favor of a form that lets you keep total exposure low.

Children and Adolescents

Bupropion is not FDA-approved for pediatric depression (only fluoxetine and escitalopram are). It is used off-label, sometimes for depression with comorbid ADHD, but only after first-line SSRIs, with the same slow titration, seizure counseling, and adherence to the class-wide suicidality boxed warning.

Part 9: Discontinuation

Stopping bupropion is easy. Its discontinuation syndrome is minimal, mild enough that it is fair to say colloquially the drug "doesn't cause withdrawal." Most patients notice little or nothing on stopping, in sharp contrast to paroxetine or venlafaxine, whose withdrawal can be miserable.

Practical approach:

• After ≥6 months at a therapeutic dose, discontinuation can be attempted; many patients stop with little or no taper.
• A brief taper is reasonable for comfort, particularly at higher doses over long durations, where rebound is slightly more likely, though still mild. That taper is nothing like the slow, hyperbolic tapers that short-half-life serotonergic drugs demand.
• For trait-level conditions (chronic low-grade dysthymia, "I need it to function"), expect that the patient may need to stay on it indefinitely or until another strategy is in place, and that is fine.
• One caveat: in a well-established responder, missing even 1-2 doses can bring a noticeable dip in mood/energy. That is loss of the therapeutic effect rather than a dangerous withdrawal. Still, mention it so patients keep adherence tight.

Part 10: Bupropion vs the Alternatives

• vs SSRIs: roughly a dozen head-to-head trials show no average efficacy difference, including, perhaps surprisingly, for anxious depression (only a 6-point response gap). The decision is made on side effects and phenotype: choose bupropion for fatigue, low motivation, weight concern, sexual-side-effect concern, smoking, or ADHD features; choose an SSRI for anxiety-predominant presentations, patients who want emotional dampening, or those sensitive to overstimulation. A growing "all else equal, lean bupropion" bias is defensible on the side-effect profile, tempered by bupropion's higher early dropout from jitteriness.
• vs SNRIs (venlafaxine, duloxetine): similar efficacy; bupropion avoids the sexual dysfunction, weight gain, and difficult withdrawal, but SNRIs cover comorbid anxiety and neuropathic pain that bupropion does not.
• vs mirtazapine: opposite profiles. Mirtazapine for the agitated, insomniac, poor-appetite, underweight patient (it sedates and drives weight up); bupropion for the fatigued, overweight patient who needs activation. These two are the field's clearest "sedating vs activating" fork.
• vs the newer branded atypicals (vilazodone, vortioxetine, levomilnacipran): none has shown a convincing advantage over generic options, and all cost more; bupropion's niche and generic price keep it ahead for its indications.
• As augmentation: bupropion added to a serotonergic antidepressant is a rational, well-tolerated combination: it covers residual anergy and sexual side effects. Mind the direction: bupropion inhibits CYP2D6, so it raises the SSRI's level rather than the reverse. The label names paroxetine, fluoxetine and sertraline among the 2D6 substrates affected; escitalopram is not on that list, which makes it the cleanest partner.

What bupropion uniquely or best delivers: weight loss (unique among antidepressants), preserved/enhanced sexual function, an energizing rather than blunting profile, an FDA smoking-cessation indication, minimal withdrawal, minimal drug interactions, and no QT or bleeding liability.

Mechanism

Bupropion is labeled an NDRI (norepinephrine-dopamine reuptake inhibitor), and in the Neuroscience-Based Nomenclature it is a norepinephrine/dopamine reuptake inhibitor and releaser, which places it, mechanistically, next to the psychostimulants. Its mechanism is incompletely understood. It is only a weak dopamine reuptake inhibitor and a modest norepinephrine reuptake inhibitor, with the metabolite hydroxybupropion contributing meaningful noradrenergic activity. It also has nicotinic acetylcholine receptor antagonism (central to smoking cessation and possibly to its antidepressant effect).

That leaves a paradox: why is bupropion an antidepressant when far more potent dopaminergic drugs (methylphenidate, amphetamine) are not? One hypothesis is that bupropion stabilizes the dopamine transporter in a "closed" configuration rather than reversing it like the stimulants, producing a gentler, sustained modulation instead of a rewarding surge. Whatever the true mechanism, the clinical effect is consistent: activation without the abuse liability and euphoria of a classical stimulant.

Pharmacokinetics in brief: half-life on the order of ~12-21 hours (parent compound; active metabolites longer), steady state in ~5-8 days, hepatic metabolism (CYP2B6 to hydroxybupropion; CYP2D6 inhibition is the interaction driver), with stimulant effects possible on day one but the antidepressant effect taking 2-4 weeks and a full trial 6-7 weeks.

The Bedside Cheat Sheet